ScholarGate
어시스턴트

방법 비교

선택한 방법을 나란히 검토하세요. 서로 다른 행은 강조 표시됩니다.

다기관 1상 임상시험×임상 1상 시험×
분야역학역학
계열Process / pipelineProcess / pipeline
기원 연도1970s–1980s (formalized in FDA Phase I guidance 1977; ICH E6 GCP 1996)1960s (formal regulatory framework established ~1963–1970s)
창시자Established through FDA regulatory guidance and ICH harmonization frameworksRegulatory and clinical pharmacology community; formalized in U.S. FDA IND regulations (1963) and ICH guidelines
유형Interventional clinical study designInterventional clinical study design
원전International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). ICH. link ↗Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. DOI ↗
별칭multisite Phase I trial, multi-institutional Phase I study, Phase I dose-escalation multicenter study, first-in-human multicenter trialPhase 1 trial, first-in-human study, FIH study, dose-escalation study
관련66
요약A multicenter Phase I clinical trial is the first systematic administration of an investigational agent to humans, conducted simultaneously across two or more clinical sites. Its primary objectives are to characterize the safety and tolerability profile of the intervention, determine the maximum tolerated dose (MTD), and describe pharmacokinetic and pharmacodynamic behavior. Distributing enrollment across sites increases participant accrual speed and enhances the generalizability of early-phase safety data.A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials.
ScholarGate데이터셋
  1. v1
  2. 2 출처
  3. PUBLISHED
  1. v1
  2. 2 출처
  3. PUBLISHED

검색으로 이동 슬라이드 다운로드

ScholarGate방법 비교: Multicenter Phase I Clinical Trial · Phase I Clinical Trial. 2026-06-19에 다음에서 검색함: https://scholargate.app/ko/compare